Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: Lack of prediction in HER2-positive disease treated with targeted therapy

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1144-1150

  Giordano, A ^a,b   Giuliano, M ^b,c   De laurentiis, M ^d   Arpino, G ^b   Jackson, S ^a   Handy, B C ^a   Ueno, N T ^a   Andreopoulou, E ^a   Alvarez, R H ^a   Valero, V ^a   De placido, S ^b   Hortobagyi, G N ^a   Reuben, J M ^a   Cristofanilli, M ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

Circulating tumor cells; HER2; Immunohistochemical subtypes; Metastatic breast cancer; Tumor markers

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ASSAY; CELLULAR DISTRIBUTION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; VISCERAL METASTASIS;

BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84860491029     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr434     Document Type: Article

References (31)

1. National Cancer InstituteNDBM. Cancer Trends Progress Report-2009/2010 Update. 2010; http://progressreport.cancer.gov (17 January 2011, date last accessed).
2. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5: 591-602.
3. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28: 3271-3277.
4. Norton L, Massague J. Is cancer a disease of self-seeding? Nat Med 2006; 12: 875-878.
5. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
6. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-1430.
7. Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12: 4218-4224.
8. Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-6409.
9. Riethdorf S, Fritsche H, Muller V et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007; 13: 920-928.
10. Nole F, Munzone E, Zorzino L et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008; 19: 891-897.
11. Dawood S, Broglio K, Valero V et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 2008; 113: 2422-2430.
12. Nakamura S, Yagata H, Ohno S et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010; 17: 199-204.
13. De Giorgi U, Valero V, Rohren E et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009; 27: 3303-3311.
14. Bidard FC, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010; 21: 1765-1771.
15. De Giorgi U, Valero V, Rohren E et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 2010; 21: 33-39.
16. Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012; 23: 618-624.
17. Giordano A, Giuliano M, De Laurentiis M et al. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Res Treat 2011; 129: 451-458.
18. Giuliano M, Giordano A, Jackson S et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011; 13: R67.
19. Liu MC, Shields PG, Warren RD et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009; 27: 5153-5159.
20. Fehm T, Muller V, Aktas B et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010; 124: 403-412.
21. Flores LM, Kindelberger DW, Ligon AH et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer 2010; 102: 1495-1502.
22. Riethdorf S, Muller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-2645.
23. Fehm T, Hoffmann O, Aktas B et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009; 11: R59.
24. The World Health Organization histological typing of breast tumors-second edition. The World Organization. Am J Clin Pathol 1982; 78: 806-816.
25. Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957; 105: 97-102.
26. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904.
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
28. Wolff AC, Dowsett M. Estrogen receptor: a never ending story? J Clin Oncol 2011; 29: 2955-2958.
29. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
30. Dawood S, Broglio K, Buzdar AU et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28: 92-98.
31. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.